Cargando…
The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets
There have been no new drugs for the treatment of schizophrenia in several decades and treatment resistance represents a major unmet clinical need. The drugs that exist are based on serendipitous clinical observations rather than an evidence-based understanding of disease pathophysiology. In the pre...
Autores principales: | Lago, Santiago G., Bahn, Sabine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956592/ https://www.ncbi.nlm.nih.gov/pubmed/35338153 http://dx.doi.org/10.1038/s41525-022-00290-4 |
Ejemplares similares
-
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19
por: Gaziano, Liam, et al.
Publicado: (2021) -
Tissue‐ and cell‐expression of druggable host proteins provide insights into repurposing drugs for COVID‐19
por: Li, Jiapeng, et al.
Publicado: (2022) -
Rapid Identification of Druggable Targets and the Power of the PHENotype SIMulator for Effective Drug Repurposing in COVID-19
por: Maria, Naomi I., et al.
Publicado: (2021) -
Anthelmintics for drug repurposing: Opportunities and challenges
por: Alavi, Seyed Ebrahim, et al.
Publicado: (2021) -
Malnutrition and disability: unexplored opportunities for collaboration
por: Groce, N, et al.
Publicado: (2014)